

BioCentury

WEEK IN REVIEW

Article Reprint • Page 1 of 1

CLINICAL NEWS

CLINICAL RESULTS

Provectus Pharmaceuticals Inc. (OTCBB:PVCT), Knoxville, Tenn.

Product: PH-10

Business: Autoimmune

Molecular target: NA

Description: Topical aqueous hydrogel formulation of Rose Bengal disodium

Indication: Treat mild to moderate plaque psoriasis

Endpoint: Treatment success as measured by the Psoriasis Severity Index (PSI) and Plaque Response Assessment scale at day 29 and safety; daily changes in PSI, Plaque Response scale and Pruritus Self-Assessment scores

Status: Phase IIc data

Milestone: NA

Top-line data from the single-blind, U.S. Phase IIc PH-10-PS-23 trial in 99 patients with mild to moderate plaque psoriasis of the trunk and/or extremities showing that 23-29% of patients receiving once-daily topical 0.002%, 0.005% or 0.01% PH-10 achieved complete or near complete resolution of all PSI component symptoms — erythema, induration and desquamation — vs. 0% for vehicle control at 28 days. Provectus also said that the 0.002% and 0.005% formulations of PH-10 showed the maximum improvements in Plaque Response Assessment, with low-dose PH-10 achieving significant improvements on the endpoint vs. vehicle control at 2 weeks ($p < 0.001$). Additionally, 38% of patients receiving low-dose PH-10 reported no itching after 28 days vs. 14% for vehicle control. PH-10 was generally well tolerated with only transient mild to occasionally moderate adverse events limited to the application site reported. Provectus did not disclose next steps.

BioCentury®
THE BERNSTEIN REPORT ON BIOBUSINESS

PO Box 1246
San Carlos CA 94070-1246
Voice: 650-595-5333
Fax: 650-595-5589
www.biocentury.com

DAVID FLORES
President & CEO

KAREN BERNSTEIN, Ph.D.
Chairman & Editor-in-Chief

BioCentury®, The BioCentury 100, and The Clear Route are trademarks of BioCENTURY PUBLICATIONS INC. All contents © Copyright 2012, BioCENTURY PUBLICATIONS INC. ALL RIGHTS RESERVED. No part of this publication may be reproduced, photocopied or reproduced in any form, retransmitted, or stored in a retrieval system without prior written consent of the publisher.

The contents of this publication are gathered from sources believed to be reliable, but in any case are not warranted by the publisher for a particular use or purpose. Also, the content and opinions herein may change without notice and do not constitute investment advice.